RE:RE:Expecting a better Q2. @telecaster_400
According to Glenn Ibott -
"Marketing expenses increased 99 percent to 29.4 million from 14.8 million in Q4 2018. Over 80 percent of the increased spend was directly related to the October 17th launch and is nonrecurring."
So (29.4 - 14.8)*.2 + 14.8 = 17.6 million as a target marketing expense.
But you are correct, I was way light on marketing and revised the amount to reflect 20 percent of the increased difference and not the Q1 expense. - Thanks!
With respect to financing activity, I purposefully didn't include these as I am only concerned in the core business of growing and selling pot. You are right again in saying financing activity is big, but it obscures the underlying picture of ACBs progress toward being cash positive from operations.
Re your comments to include MedReleaf expense, they are included in the Q1 consolidated results from which I base Q2. While the G&A is expected to normalize lower, I've increased Q2 to account for acquisitions and headcount.
